Public Controversies

Berger Montague Announces Class Action Lawsuit Against Tenax Therapeutics, Inc. and Sets Lead Plaintiff Deadline

· GlobeWire Daily Editorial Desk · Source: www.prnewswire.com

2 min read

Key takeawaysBerger Montague has announced a class action lawsuit filed against Tenax Therapeutics, Inc. (NASDAQ: TENX) and certain officers on behalf of investors who purchased securities between November 13, 2023, and August 7, 2026. The complaint alleges violations of federal securities laws regarding the prospects of the company's lead drug candidate, TNX-103…
Berger Montague Announces Class Action Lawsuit Against Tenax Therapeutics, Inc. and Sets Lead Plaintiff Deadline

Original GlobeWire Daily editorial illustration — not an event photograph.

Berger Montague has announced a class action lawsuit filed against Tenax Therapeutics, Inc. (NASDAQ: TENX) and certain officers on behalf of investors who purchased securities between November 13, 2023, and August 7, 2026. The complaint alleges violations of federal securities laws regarding the prospects of the company's lead drug candidate, TNX-103 (oral levosimendan). Investors wishing to serve as lead plaintiff must apply by December 28, 2026.

Lawsuit Overview and Allegations

The complaint, filed in the United States District Court for the Middle District of North Carolina (Case No. 26-cv-01624), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

  • Challenged Period: November 13, 2023, through August 7, 2026.
  • Alleged Misstatements: The lawsuit alleges that defendants overstated the clinical, regulatory, and commercial prospects of TNX-103, which was being developed for pulmonary hypertension in patients with heart failure with preserved ejection fraction (PH-HFpEF).
  • Core Claims: According to the complaint, defendants promoted the development approach as "derisked" but allegedly failed to disclose that TNX-103 was less effective than led to believe.

Disclosures and Stock Price Impact

The complaint states that the issues began to emerge on August 10, 2026, when Tenax announced topline results from the Phase 3 LEVEL trial.

  • Trial Outcome: Tenax disclosed that TNX-103 failed to meet its primary endpoint of improving six-minute walk distance versus placebo, as well as its key secondary endpoint of improving the Kansas City Cardiomyopathy Questionnaire total symptom score.
  • Market Reaction: Following the announcement, Tenax's stock price reportedly fell approximately $12.06 per share, or 89.77%, closing at approximately $1.38 per share on August 10, 2026.

Investor Participation and Deadlines

  • Lead Plaintiff Deadline: December 28, 2026, is the deadline for eligible investors to seek appointment as lead plaintiff.
  • Verification and Contact: Investors can review the filed court documents or contact Berger Montague representatives Andrew Abramowitz or Caitlin Adorni via the firm's official channels to discuss their rights and the litigation process.
Share this article
Read the original source: INVESTOR REMINDER: Berger Montague Notifies Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors of a Class Action Lawsuit and Deadline

AI-assisted reporting; source claims are attributed and have not been independently verified.

About the author

GlobeWire Daily Editorial Desk — AI-assisted news based on attributed published sources.

More to read